Prestigious Cabernet producer aims to raise $250,000 for groundbreaking cancer research through limited October release
SNOHOMISH, Wash., – In honor of Cancer Awareness Month, Quilceda Creek President Paul Golitzin and General Manager Scott Lloyd announced today that beginning Oct. 27, the winery will release a rare collection of library wines in support of the Cancer Research Institute (CRI). Fifty percent from every bottle sold will be donated to CRI, with a fundraising goal of $250,000.
Founded in 1978, Quilceda Creek is among Washington State’s most celebrated family-owned wineries and has garnered more 100-point scores from leading critics on its Cabernet Sauvignons than nearly any other American producer. Typically, its wines are allocated exclusively to members of the private mailing list. For this special #QuilcedaCares campaign, however, the Golitzin family will make a limited number of highly sought-after library wines available to the public—a release only the second of its kind in the winery’s 48-year history.
“Each of us knows someone who has been impacted by cancer, and the work done by CRI is extraordinary in its ability to turn research into real hope for individuals and families,” said Golitzin. “We are honored to support its mission and proud to contribute to discoveries that are changing lives.”
Since 1953, CRI has been at the forefront of advancing cancer immunotherapy by empowering people, illuminating biological breakthroughs, and more recently, harnessing and unlocking the power of data. A top-rated nonprofit, CRI convenes scientists, funders, and patients to drive breakthroughs in cancer immunotherapy and advance its mission to create a world immune to cancer.
“Partnerships like this remind us that science doesn’t happen in isolation–it’s powered by people and communities who care,” said Alicia Zhou, PhD, CEO of CRI. “Quilceda Creek’s generosity helps fuel discoveries that bring cancer treatments closer to every patient, everywhere. Together, we’re turning shared passion into tangible progress toward a world immune to cancer.”
The library release will go live on Monday, Oct. 27 and continue until sold out. To further maximize its impact, Quilceda Creek will also offer a one-time opportunity for new members to join its private mailing list—bypassing the standard 12- to 24-month waitlist if they support this life-saving cause with a purchase. Those interested in receiving an offer may do so by signing up for the mailing list before Oct. 27, or by calling the winery at (800) 877-4270.
The campaign will include library Quilceda Creek Columbia Valley Cabernet Sauvignon in a vertical 6- and 12-bottle format, along with a 1.5L offering. This iconic Cabernet Sauvignon made history as the first wine outside California to earn a 100-point score from Robert Parker’s Wine Advocate (2002 vintage). This release represents a rare chance for collectors to acquire Quilceda Creek’s most treasured wines while directly supporting pioneering cancer research.
For more information about Quilceda Creek, please visit https://www.quilcedacreek.com/
About Quilceda Creek
Quilceda Creek was established in 1978 by Alex and Jeannette Golitzin. The winery’s first vintage was in 1979, making Quilceda Creek the 12th-oldest winery in Washington after Prohibition. Alex Golitzin’s inspiration to start the winery was nurtured through many visits to the Napa Valley in his youth, where he spent time with his maternal uncle, André Tchelistcheff, the legendary Napa Valley winemaker known as the “Dean of American Winemaking.” Paul Golitzin joined his father as winemaker in 1992 and as president of the company today, directs all aspects of vineyard management and winemaking. With a gifted palate and a no-compromise commitment to quality, Paul focused the winery’s attention on its greatest assets: the vineyards of the Columbia Valley. Quilceda Creek wines are an expression of four vineyards: Champoux, Galitzine, Mach One, and Galitzine-Ad Astra. In early 2022, Quilceda Creek welcomed Mark Kaigas as winemaker.
About Cancer Research Institute
The Cancer Research Institute (CRI) is a nonprofit organization dedicated to advancing the field of cancer immunotherapy through rigorous scientific research and global collaboration. Since 1953, CRI has been instrumental in uncovering the fundamental biology of the immune system and its application to cancer treatment, laying the groundwork for breakthroughs such as checkpoint blockade, cancer vaccines, and engineered cell therapies. To date, CRI has committed over $560 million to research impacting more than 30 cancer types. The organization’s funding strategy is built on the framework of People × Biology × Data: supporting world-class scientists, deepening understanding of tumor-immune system interactions, and harnessing data to guide discovery and translation. By uniting these elements, CRI catalyzes innovation through its global research ecosystem to drive the next generation of discoveries forward.
